United States Somatic Genetic Testing Market Size & Outlook, 2026-2034

United States Somatic Genetic Testing Market Insights

Deep Market Insights analysis indicates that the United States Somatic Genetic Testing Market size, valued at USD 1238.55 Million in 2025, is expected to expand to USD 5382.98 Million by 2034.
The United States market is forecasted to expand at a CAGR of 17.88% spanning 2026–2034.
Tumor profiling tests held the leading position among By Test Type segments in 2025, based on market size.
Predictive genetic tests is projected to post the fastest growth rate, sustaining its position as the most attractive By Test Type segment during the forecast horizon.

United States contributed 23.41% to the global Somatic Genetic Testing Market size in 2025.
By 2034, United States is forecasted to remain the largest global market for Somatic Genetic Testing Market.
In North America, United States is projected to capture the leading share of market size by 2034.
Among North America markets, United States is expected to post the fastest growth, reaching USD 5443.46 Million by 2034.

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 1238.55 Million
Market Size In 2034	USD 5382.98 Million
Largest segment	Tumor profiling tests
Units	Revenue in USD Million
CAGR	17.88% (2026-2034)
Segmnetation Covered
By Test Type	Tumor profiling tests Carrier screening Predictive genetic tests Diagnostic genetic tests
By Technology	Next-generation sequencing PCR-based testing Microarray testing Sanger sequencing
By Application	Oncology Rare diseases Prenatal testing Personalized medicine
By End User	Hospitals Diagnostic laboratories Research institutes Clinics
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

By Test Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Tumor profiling tests	XX.x	XX.x	XX.x	560.57	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Carrier screening	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Predictive genetic tests	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Diagnostic genetic tests	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Technology	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Next-generation sequencing	XX.x	XX.x	XX.x	557.6	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
PCR-based testing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Microarray testing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Sanger sequencing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Application	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Oncology	XX.x	XX.x	XX.x	495.92	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Rare diseases	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Prenatal testing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Personalized medicine	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By End User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	536.04	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Diagnostic laboratories	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Research institutes	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x